# Project Charter: NYSE Pharma-Performance Linear Regression Model

## 1. Project Overview
- **Title:** Linear Regression Model for Pharmaceutical Sector Performance Prediction
- **Date:** Jun 18, 2024
- **Project Manager:** Mandy Wu

## 2. Project Objective
Develop a linear regression model to predict pharmaceutical sector performance using economic, market, and industry-specific indicators.

## 3. Business Case
Accurate predictions will:
- Inform investor decisions
- Aid pharmaceutical companies in strategic planning
- Assist policymakers in understanding sector dynamics

## 4. Project Scope
### In Scope:
- Data collection and preprocessing
- Exploratory Data Analysis (EDA)
- Feature engineering and selection
- Linear regression model development and training
- Model evaluation and refinement
- Basic model deployment and monitoring setup

### Out of Scope:
- Real-time data integration
- Advanced machine learning models
- User interface development
- Integration with existing financial systems

## 5. Deliverables
- Cleaned dataset
- EDA report
- Trained and validated model
- Model performance report
- Deployment and monitoring scripts
- Final project report and presentation

## 6. Stakeholders
- **Domain Experts:**
- **End Users:** Anyone who is interested

## 7. Timeline
- **Start Date:** 
- **End Date:** 
- **Duration:** 

## 8. Key Milestones
- Data preparation: Week 2
- EDA and feature engineering: Week 4
- Initial model: Week 6
- Model refinement: Week 8
- Deployment: Week 10
- Documentation: Week 12

## 9. Budget
**Total:** $[Amount]
### Breakdown:
- Software/Tools: $[Amount]


## 10. Key Challenges and Mitigation Strategies

**Data Quality and Availability**
- **Challenge:** Inconsistent or missing data across sources.
- **Mitigation:**
  - Implement robust data validation checks
  - Use multiple data sources for cross-verification
  - Develop imputation strategies for missing data
  - Establish contingency plans for data source failures

**Feature Engineering Complexity**
- **Challenge:** Creating relevant, predictive features for the pharmaceutical sector.
- **Mitigation:**
  - Collaborate with domain experts in pharmaceutical finance
  - Conduct iterative feature development and testing
  - Implement automated feature selection techniques
  - Maintain a feature store for reusability and consistency

**Model Performance and Stability**
- **Challenge:** Achieving consistent performance in a volatile pharmaceutical market.
- **Mitigation:**
  - Implement ensemble methods to improve stability
  - Use rolling window approach for model training
  - Regularly retrain the model with new market data
  - Set up automated model performance monitoring and alerting

**Regulatory Compliance**
- **Challenge:** Ensuring adherence to financial regulations and data privacy laws.
- **Mitigation:**
  - Consult with legal experts on compliance requirements for financial models
  - Implement data anonymization techniques for sensitive information
  - Establish clear data governance policies specific to pharmaceutical data
  - Conduct regular compliance audits and documentation reviews

**Interpretability vs. Complexity**
- **Challenge:** Balancing model complexity with interpretability for stakeholders.
- **Mitigation:**
  - Use explainable AI techniques (e.g., SHAP values) for the linear regression model
  - Develop intuitive visualizations for model outputs and feature importances
  - Provide layered explanations for different audience levels (technical vs. non-technical)
  - Conduct regular stakeholder feedback sessions on model interpretability

**Time Management**
- **Challenge:** Adhering to the project timeline amidst unforeseen issues
- **Mitigation:**
  - Build buffer time into each project phase, especially data collection and preprocessing
  - Implement agile project management methodologies with weekly sprints
  - Prioritize tasks based on impact and urgency for the LR model development
  - Conduct regular progress reviews and adjust timeline as needed

**Technical Debt**
- **Challenge:** Balancing rapid development with code quality and maintainability.
- **Mitigation:**
  - Establish coding standards and review processes specific to data science projects
  - Implement continuous integration/continuous deployment (CI/CD) for model updates
  - Schedule regular refactoring sessions for the codebase
  - Maintain comprehensive documentation of the model architecture and data pipeline

**Scalability**
- **Challenge:** Ensuring the model can handle increasing data volumes and complexity.
- **Mitigation:**
  - Design scalable data architecture from the outset, considering future data growth
  - Use cloud computing resources for flexibility in processing power
  - Implement efficient data processing techniques (e.g., batch processing for large datasets)
  - Regularly assess and optimize system performance for the LR model

**Stakeholder Expectations**
- **Challenge:** Managing diverse expectations from various stakeholders in pharmaceutical finance
- **Mitigation:**
  - Clearly define and communicate project scope and limitations of the LR model
  - Provide regular updates and demonstrations of model performance
  - Establish a feedback loop for continuous improvement of model outputs
  - Develop a comprehensive stakeholder management plan tailored to finance and pharma sectors

**Team Skill Gaps**
- **Challenge:** Addressing potential skill shortages within the team for specialized pharma-finance modeling
- **Mitigation:**
  - Conduct skills assessment at project initiation, focusing on linear regression and time series analysis
  - Provide targeted training on pharmaceutical sector financial analysis
  - Consider bringing in external experts for specialized tasks (e.g., healthcare policy impact)
  - Foster a culture of knowledge sharing within the team on pharma-specific modeling techniques

By anticipating these challenges and implementing proactive mitigation strategies, we can increase the likelihood of successful completion of the NYSE Pharma-Performance LR Model project within the estimated timeframe. Regular risk assessments and flexibility in approach will be key to navigating unforeseen obstacles in the dynamic pharmaceutical market.

## 11. Success Criteria
- R-squared â‰¥ 0.7 on test data
- Mean Absolute Error < 2% of average daily return
- Stakeholder validation of model insights
- Completion within timeline and budget

## 12. Approval
- **Project Manager:** [Your Signature]
- **Date:** Jun 18, 2024

# Project Timeline and Milestones

**Duration:** 
**Start Date:** 
**End Date:** 

## Week 1-2: Data Collection and Preprocessing
### Milestone 1 (End of Week 2): Dataset Ready

**Deliverables:**
- Cleaned, integrated dataset
- Data quality report
- Initial Data Dictionary

## Week 3-4: Exploratory Data Analysis (EDA) and Feature Engineering
### Milestone 2 (End of Week 4): EDA Complete

**Deliverables:**
- EDA report with visualizations
- List of engineered features
- Updated Data Dictionary

## Week 5-6: Initial Model Development
### Milestone 3 (End of Week 6): Baseline Model

**Deliverables:**
- Trained linear regression model
- Initial performance metrics
- Feature importance analysis

## Week 7-8: Model Refinement and Validation
### Milestone 4 (End of Week 8): Refined Model

**Deliverables:**
- Optimized model with cross-validation results
- Comparative analysis with baseline model
- Finalized feature set

## Week 9-10: Model Deployment and Monitoring Setup
### Milestone 5 (End of Week 10): Model Deployed

**Deliverables:**
- Deployment scripts
- Basic monitoring system
- User guide for model application

## Week 11-12: Documentation and Presentation
### Milestone 6 (End of Week 12): Project Completion

**Deliverables:**
- Final project report
- Presentation slides
- Code repository with documentation

## Key Considerations:

1. **Buffer Time:** Each phase includes some buffer time for unexpected issues.
2. **Iterative Approach:** Phases may overlap, allowing for iterative improvements.
3. **Checkpoints:** Schedule brief weekly check-ins to track progress and address issues promptly.
4. **Flexibility:** Be prepared to adjust the timeline if early phases reveal unexpected complexities or opportunities.
5. **Stakeholder Reviews:** Plan for stakeholder reviews at each milestone to ensure alignment and gather feedback.
6. **Documentation:** Continuously update project documentation throughout the timeline.
7. **Risk Management:** Regularly assess risks and adjust the timeline if necessary.
